Dual Role of DUOX1-Derived Reactive Oxygen Species in Melanoma

Antioxidants (Basel). 2023 Mar 13;12(3):708. doi: 10.3390/antiox12030708.

Abstract

Melanoma is the most serious type of skin cancer. Inflammation and oxidative stress play an essential role in the development of several types of cancer, including melanoma. Although oxidative stress promotes tumor growth, once cells escape from the primary tumor, they are subjected to a more hostile environment, with higher levels of oxidative stress typically killing most cancer cells. As Dual Oxidase 1 (DUOX1) is a major producer of reactive oxygen species (ROS) in epithelia, we used allotransplantation and autochthonous melanoma models in zebrafish together with in silico analysis of the occurrence and relevance of DUOX1 expression of the skin cutaneous melanoma (SKCM) cohort of The Cancer Genome Atlas (TCGA) to address the role of this enzyme in the aggressiveness of melanoma cells in vivo. It was found that high transcript levels of the gene encoding DUOX1 were associated with the poor prognosis of patients in the early-stage melanoma of TCGA cohort. However, DUOX1 transcript levels were not found to be associated to the prognosis of late-stage SKCM patients. In addition, the transcript level of DUOX1 in metastatic SKCM was lower than in primary SKCM. Using zebrafish primary melanoma and allotransplantation models, we interrogated the role of DUOX1 in vivo. Our results confirmed a dual role of DUOX1, which restrains melanoma proliferation but promotes metastasis. As this effect is only observed in immunocompromised individuals, the immune system appears to be able to counteract this elevated metastatic potential of DUOX1-deficient melanomas.

Keywords: DUOX1; melanoma; metastasis; oxidative stress; reactive oxygen species; zebrafish.

Grants and funding

This work was supported by grants BIO2017-84702-R and PID2020-113660RB-I00 to V.M. funded by MCIN/AEI/10.13039/501100011033, Miguel Servet CP21/00028 contract to D.G.-M. funded by Instituto de Salud Carlos III, and PhD fellowship to I.P.-S. funded by Asociación Española Contra el Cáncer (AECC).